Corrigendum to Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferences: Am J Obstet Gynecol 225 (2021) 658.e1-658.e9/Article 658.

Autor: Madariaga A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain., Bhat G; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada., Wilson MK; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada., Li X; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Cyriac S; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada., Bowering V; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Hunt W; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Gutierrez D; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Bonilla L; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada., Kasherman L; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada., McMullen M; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada., Wang L; University of Toronto, Toronto, Ontario, Canada; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Ghai S; University of Toronto, Toronto, Ontario, Canada; Department of Medical Imaging, University Health Network, Toronto, Ontario, Canada., Dhani NC; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada., Oza AM; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada., Lheureux S; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada. Electronic address: stephanie.lheureux@uhn.ca.

Publikováno v: American journal of obstetrics and gynecology [Am J Obstet Gynecol] 2024 Jul; Vol. 231 (1), pp. 141. Date of Electronic Publication: 2024 Apr 27.

FBXW7-loss Sensitizes Cells to ATR Inhibition Through Induced Mitotic Catastrophe.

Autor: O'Brien S; Department of Biochemistry, University of Toronto, Ontario, Canada.; Terrence Donnelly Centre for Cellular and Biomolecular Research, Toronto, Ontario, Canada., Ubhi T; Department of Biochemistry, University of Toronto, Ontario, Canada.; Terrence Donnelly Centre for Cellular and Biomolecular Research, Toronto, Ontario, Canada., Wolf L; Terrence Donnelly Centre for Cellular and Biomolecular Research, Toronto, Ontario, Canada., Gandhi K; Terrence Donnelly Centre for Cellular and Biomolecular Research, Toronto, Ontario, Canada., Lin S; Terrence Donnelly Centre for Cellular and Biomolecular Research, Toronto, Ontario, Canada., Chaudary N; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Ontario Cancer Institute, Toronto, Ontario, Canada., Dhani NC; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Milosevic M; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Department of Radiation Oncology, University of Toronto, Ontario, Canada.; Institute of Medical Science, University of Toronto, Ontario, Canada., Brown GW; Department of Biochemistry, University of Toronto, Ontario, Canada.; Terrence Donnelly Centre for Cellular and Biomolecular Research, Toronto, Ontario, Canada., Angers S; Department of Biochemistry, University of Toronto, Ontario, Canada.; Terrence Donnelly Centre for Cellular and Biomolecular Research, Toronto, Ontario, Canada.; Leslie Dan Faculty of Pharmacy, University of Toronto, Ontario, Canada.

Publikováno v: Cancer research communications [Cancer Res Commun] 2023 Dec 21; Vol. 3 (12), pp. 2596-2607.

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression.

Autor: Lheureux S; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Prokopec SD; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Oldfield LE; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Gonzalez-Ochoa E; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Bruce JP; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Wong D; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Danesh A; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Torti D; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Torchia J; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Fortuna A; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Singh S; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Irving M; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Marsh K; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Lam B; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Speers V; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Yosifova A; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Oaknin A; Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Madariaga A; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Dhani NC; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Bowering V; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Oza AM; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Pugh TJ; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Sep 15; Vol. 29 (18), pp. 3706-3716.

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.

Autor: Madariaga A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; University of Toronto, Toronto, ON, Canada.; Autonomous University of Barcelona, Barcelona, Spain.; Department of Medical Oncology, 12 de Octubre University Hospital, Madrid, Spain., Garg S; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Tchrakian N; University of Toronto, Toronto, ON, Canada.; Department of Pathology and Laboratory Medicine, University Health Network, Toronto, ON, Canada., Dhani NC; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; University of Toronto, Toronto, ON, Canada., Jimenez W; Division of Gynecologic Oncology, Juravinski Cancer Centre, Hamilton, ON, Canada., Welch S; Division of Medical Oncology and Hematology, London Health Sciences Center, London Regional Cancer Program, London, ON, Canada., MacKay H; Division of Medical Oncology and Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Ethier JL; Division of Medical Oncology and Hematology, Kingston Health Sciences Cancer Centre, Kingston, ON, Canada., Gilbert L; Division of Gynecologic Oncology, McGill University Health Centre, Royal Victoria Hospital, Montréal, QC, Canada., Li X; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Rodriguez A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Chan L; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Bowering V; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Clarke B; University of Toronto, Toronto, ON, Canada.; Department of Pathology and Laboratory Medicine, University Health Network, Toronto, ON, Canada., Zhang T; Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada., King I; Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada., Downs G; Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada., Stockley T; Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada., Wang L; University of Toronto, Toronto, ON, Canada.; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Udagani S; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Oza AM; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; University of Toronto, Toronto, ON, Canada., Lheureux S; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. stephanie.lheureux@uhn.ca.; University of Toronto, Toronto, ON, Canada. stephanie.lheureux@uhn.ca.

Publikováno v: Nature communications [Nat Commun] 2023 Mar 15; Vol. 14 (1), pp. 1452. Date of Electronic Publication: 2023 Mar 15.

Digital quantitative tissue image analysis of hypoxia in resected pancreatic ductal adenocarcinomas.

Autor: Siddiqui I; Department of Pediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada., Bilkey J; Spatio-temporal Targeting and Amplification of Radiation Response (STTARR), University Health Network, Toronto, ON, Canada., McKee TD; Spatio-temporal Targeting and Amplification of Radiation Response (STTARR), University Health Network, Toronto, ON, Canada., Serra S; Department of Pathology, Toronto General Hospital, Toronto, ON, Canada., Pintilie M; Department of Biostatistics, The Princess Margaret Cancer Centre, Toronto, ON, Canada., Do T; Spatio-temporal Targeting and Amplification of Radiation Response (STTARR), University Health Network, Toronto, ON, Canada., Xu J; Department of Medical Oncology, The Princess Margaret Cancer Centre, Toronto, ON, Canada., Tsao MS; Department of Pathology, Toronto General Hospital, Toronto, ON, Canada., Gallinger S; PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, ON, Canada.; Hepato-Pancreatico-Biliary Surgical Oncology Program, University Health Network, Toronto, ON, Canada., Hill RP; Medicine Program, The Princess Margaret Cancer Centre/Ontario Cancer Institute, Radiation Toronto, ON, Canada., Hedley DW; Department of Medical Oncology, The Princess Margaret Cancer Centre, Toronto, ON, Canada., Dhani NC; Department of Medical Oncology, The Princess Margaret Cancer Centre, Toronto, ON, Canada.

Publikováno v: Frontiers in oncology [Front Oncol] 2022 Aug 01; Vol. 12, pp. 926497. Date of Electronic Publication: 2022 Aug 01 (Print Publication: 2022).